International Team Plans Fusion Test

LONDON—A team of 40 scientists from the United States, Western Europe, Japan and the Soviet Union plans to begin work next spring on a three-year, $180 million effort to design the next large thermonuclear fusion experiment. If the participants accept the design, construction of the International Thermonuclear Experimental Reactor (ITER) could begin as early as 1993. Meeting last month in Vienna, officials from each of the participants also agreed on a European site for the project. It

Written byTom Wilkie
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

LONDON—A team of 40 scientists from the United States, Western Europe, Japan and the Soviet Union plans to begin work next spring on a three-year, $180 million effort to design the next large thermonuclear fusion experiment. If the participants accept the design, construction of the International Thermonuclear Experimental Reactor (ITER) could begin as early as 1993.

Meeting last month in Vienna, officials from each of the participants also agreed on a European site for the project. It will be housed in a new facility at the Max Planck Institute for Plasma Physics in Garching, outside Munich. The site selection was a contentious issue, with the Americans arguing for Lawrence Livermore National Laboratory. The compromise offer of Vienna, the home of the U.N. International Atomic Energy Agency, was also rejected, but the Europeans did agree to balance their geographic victory with an advisory board that would be chaired jointly by officials ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies